These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29055130)

  • 1. Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
    Bassiouny YA; Dakhly DMR; Bayoumi YA; Salaheldin NM; Gouda HM; Hassan AA
    Int J Gynaecol Obstet; 2018 Feb; 140(2):217-222. PubMed ID: 29055130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Esinler I; Bozdag G; Karakocsokmensuer L
    Arch Gynecol Obstet; 2013 Nov; 288(5):1159-63. PubMed ID: 23677417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
    J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention.
    Bushaqer NJ; Dayoub NM; AlHattali KK; Ayyoub HA; AlFaraj SS; Hassan SN
    Saudi Med J; 2018 Mar; 39(3):290-295. PubMed ID: 29543308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline for preventing ovarian hyperstimulation syndrome.
    Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome.
    Chen CD; Chao KH; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 2003 Jul; 80(1):86-90. PubMed ID: 12849806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of coasting on cycle outcome during in vitro fertilization/intracytoplasmic sperm injection cycles in hyper-responders.
    Kovács P; Mátyás S; Kaali SG
    Fertil Steril; 2006 Apr; 85(4):913-7. PubMed ID: 16580374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH antagonist rescue of a short-protocol IVF/ICSI cycle and GnRH agonist triggering to prevent ovarian hyperstimulation syndrome: two case reports.
    Bakas P; Boutas I; Giner M; Panagopoulos P; Aravantinos L
    Clin Exp Obstet Gynecol; 2017; 44(2):279-282. PubMed ID: 29746040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
    Lin YH; Huang MZ; Hwang JL; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Seow KM
    J Assist Reprod Genet; 2013 Jun; 30(6):753-9. PubMed ID: 23606010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premature Progesterone Elevation Does Not Affect Pregnancy Outcome in High-Responder Patients Undergoing Short-Interval Coasting in IVF Cycles.
    Acet M; Aktün LH; Başaranoğlu S; Yorgunlar B; Acet T; Deregözü A
    Med Sci Monit Basic Res; 2015 Nov; 21():247-52. PubMed ID: 26634938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Internal coasting" for prevention of ovarian hyperstimulation syndrome (OHSS) in IVF/ICSI.
    Lukaszuk K; Liss J; Jakiel G
    Ginekol Pol; 2011 Nov; 82(11):812-6. PubMed ID: 22384612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jul; 34(7):616-622. PubMed ID: 29334275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
    Shaltout A; Shohyab A; Youssef MA
    Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):254-8. PubMed ID: 22948132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.